AI-Driven Virtual Care Moves From Pilot to Core Infrastructure
Artificial intelligence has moved from the edges of US healthcare delivery into the operational core of health systems, as providers scale virtual care, clinical decision support (CDS), and workflow automation to manage rising acuity, staffing shortages, and reimbursement pressure. While AI in healthcare is not new, the current phase is defined by large-scale deployment, integration with electronic health records (EHRs), and the translation of AI outputs into billable, regulated care encounters.
Recent industry analysis estimates that the global AI in healthcare market was valued at around $41.8 billion in 2025 and may exceed $1.1 trillion by 2035, implying a compound annual growth rate above 30%.[2] Although this is a global figure, US health systems represent a disproportionate share of both spending and early adoption, particularly in virtual triage, remote monitoring, imaging diagnostics, and automated documentation.
At the same time, academic and policy stakeholders are moving to systematize oversight. Researchers affiliated with the Mount Sinai Health System announced a first-of-its-kind index to track the evolving policy landscape for AI in healthcare, designed to catalog regulatory actions, guidance, and standards that affect AI tools used in clinical settings.[3] The creation of this framework underscores that AI’s expansion in care delivery is now a policy and compliance issue for hospital operators, payers, and technology vendors, not merely an IT or innovation initiative.
Strategic Drivers: Cost Containment, Labor Constraints, and Policy Visibility
Three structural forces are driving US health systems to scale AI-enabled virtual care and decision support:
Persistent labor shortages and wage inflation across nurses, technicians, and physicians.
Reimbursement pressure from Medicare, Medicaid, and commercial payers emphasizing value-based care and documentation accuracy.
Growing regulatory clarity and policy tracking around health AI, which reduces perceived adoption risk for large health systems.[3]
Virtual care tools – including AI-assisted symptom checkers, triage bots, and asynchronous telehealth workflows – allow systems to expand panel sizes and manage chronic disease populations without proportional increases in staff. AI-based CDS tools embedded in EHRs help clinicians prioritize high-risk patients, standardize guideline-concordant care, and reduce time spent on chart review.
On the revenue side, AI can enhance coding accuracy, support risk adjustment, and reduce claim denials through better documentation, particularly under Medicare Advantage and other value-based arrangements. As AI policy tracking improves and frameworks around data governance and bias mitigation mature, compliance departments increasingly view AI as manageable rather than existential risk.
Digital Health Companies: From Point Solutions to Infrastructure Bets
For publicly traded and late-stage private digital health companies, the shift in US health systems toward scaled AI-driven virtual care and CDS redraws the competitive map. Investors are distinguishing between:
AI-native platforms that embed machine learning into clinical workflows, documentation, and triage, and
Legacy telehealth or software vendors that provide largely manual virtual encounters with limited automation.
Recent market research underscores that leading AI healthcare players increasingly span multiple functions – from diagnostics and predictive analytics to care coordination and administrative automation – rather than offering narrow, single-use tools.[1] That breadth positions them to win enterprise-wide contracts with health systems seeking unified platforms instead of fragmented point solutions.
From an equity perspective, the medium-term opportunity set is concentrated in several categories:
Virtual care platforms with embedded AI: Companies that combine telehealth, remote monitoring, and AI-driven triage can capture growing wallet share as health systems re-platform digital front doors.
Clinical decision support and imaging AI vendors: Firms that have secured regulatory clearance for diagnostic support tools (e.g., radiology, cardiology) and that can integrate with major EHRs stand to benefit from scaled adoption as hospitals pursue operating leverage.
AI-enabled revenue cycle and documentation solutions: Vendors that automate note generation, coding, and claims management are leveraged to the push for administrative cost reduction and accurate reimbursement in value-based contracts.
However, the Mount Sinai-backed AI policy index underscores a growing requirement: digital health companies must build robust compliance, auditability, and explainability into their products to remain investable at scale.[3] Systems that cannot demonstrate bias mitigation, data protection, and alignment with emerging standards risk being sidelined in enterprise RFPs, regardless of their technical performance.
Impact on Hospital and Healthcare Provider Stocks
For US hospital operators and integrated delivery systems, AI-driven virtual care and CDS are increasingly positioned as margin protection tools. Organizations that successfully deploy scalable virtual programs can:
Shift lower-acuity encounters out of high-cost hospital settings to virtual or outpatient channels.
Improve bed utilization by better predicting admission risk and discharge readiness.
Enhance care coordination for complex patients, reducing readmissions and penalties.
Case studies beyond the US, such as Phuong Dong Hospital’s use of advanced digital infrastructure to achieve improved uptime and faster clinical image access, provide a directional analog: networked, data-rich environments enable more efficient and reliable clinical operations, supporting throughput and patient experience.[6] For US-listed hospital chains, similar AI-enabled efficiency gains could translate into higher EBITDA margins over a multi-year horizon, particularly if they reduce reliance on contract labor and overtime.
That said, AI deployment is capital-intensive and operationally complex. Health systems with strong balance sheets and robust IT teams are better positioned to absorb integration costs. Investors may therefore see a widening performance gap between:
Scale operators able to standardize AI-enabled workflows across multi-state networks, and
Smaller regional systems that lack capital and technical depth, becoming more reliant on managed service arrangements or potential consolidation.
In the near term, most hospital and provider stocks will likely reflect AI-driven virtual care as a qualitative tailwind rather than a discrete revenue line. But as adoption scales and evidence accumulates that AI-supported workflows reduce labor intensity per encounter, the market is likely to reward operators demonstrating measurable productivity gains, such as lower cost per adjusted admission or improved revenue-cycle metrics.
Insurance Providers: Utilization, Network Strategy, and Risk Scoring
US health insurers see AI-enabled virtual care as a double-edged instrument. On one side, virtual-first models and AI triage can lower total cost of care by directing members to appropriate sites of care, promoting early intervention, and supporting chronic disease management. On the other, payer medical cost trends could be pressured if AI tools surface previously undiagnosed risk at scale or stimulate additional diagnostic utilization.
From a risk-scoring perspective, AI-enhanced documentation and CDS may raise risk adjustment factors in Medicare Advantage and Medicaid managed care, as comorbidities are more consistently captured. That dynamic can be beneficial for insurers that maintain strong compliance controls and are comfortable operating under closer regulatory scrutiny.
Insurers are also increasingly evaluating AI capabilities in network contracting. Digital health vendors and provider groups that can demonstrate robust AI-enabled population health management – for example, predictive models that flag deteriorating patients or non-adherent members – can make a stronger case for value-based contracts and shared savings arrangements. Over time, payers may favor virtual-forward, AI-enabled providers within their networks, reinforcing a structural advantage for scaled digital platforms over traditional brick-and-mortar-only groups.
For publicly traded insurers, the AI virtual care trend intersects with their own internal AI strategies in claims adjudication, fraud detection, and customer engagement. While not directly captured in the Mount Sinai policy index, insurers must ensure that their use of AI in utilization management and prior authorization aligns with emerging regulatory expectations around fairness, transparency, and appeal rights.[3] Any perceived misuse of AI in benefit denial decisions could invite heightened oversight and reputational risk.
Policy and Regulatory Backdrop: Toward Structured Oversight of Health AI
The most consequential development for healthcare investors may not be any single AI application, but the emerging infrastructure for policy and oversight. The Mount Sinai-led initiative to build an index of AI policy activity in healthcare reflects a recognition that AI is now embedded in critical clinical decisions, reimbursement processes, and data flows.[3]
This index is designed to track:
Legislative actions and pending bills related to health AI.
Regulatory guidance from agencies responsible for healthcare, privacy, and medical devices.
Standards and frameworks developed by professional societies, standards bodies, and international organizations.
For market participants, the practical implication is that AI risk is becoming more quantifiable and monitorable. As policy positions are cataloged and trends identified, boards and management teams at hospitals, insurers, and digital health firms can better anticipate regulatory shifts and adjust product roadmaps and compliance programs accordingly.
This structured visibility tends to lower the risk premium investors assign to AI-driven business models, provided that companies proactively align with emerging best practices around data governance, algorithmic fairness, and patient consent. Firms that can demonstrate independent validation of their AI tools and clear governance processes are likely to gain a competitive edge in enterprise procurement and payer contracting.
Key Risks: Data Governance, Bias, and Operational Execution
Despite its growth trajectory, AI-driven virtual care and CDS face several material risks that investors must incorporate into valuation and scenario analysis:
Data privacy and security: AI systems require large volumes of sensitive health data. Breaches or misuse can trigger regulatory penalties and erode patient trust.
Algorithmic bias and clinical safety: Inadequately validated models may underperform in certain demographic groups or clinical contexts, leading to inequitable care or adverse events.
Workflow integration risk: Poorly integrated AI tools can increase clinician workload rather than reduce it, contributing to burnout and low adoption.
Regulatory non-compliance: As policy frameworks solidify, AI products that lack transparency or auditability may face restrictions or require costly redesigns.
Academic perspectives on AI in healthcare emphasize the need for extensive staff training, robust data-handling practices, and clear governance to avoid data theft and misuse, particularly when scaling AI systems in complex health environments.[5] These operational considerations will influence the pace and depth of AI adoption, particularly within risk-averse provider organizations.
Investment Implications Across the Healthcare Stack
For institutional investors, the current phase of AI-driven virtual care expansion suggests several thematic positioning angles across healthcare equities:
Overweight scalable AI platforms and infrastructure enablers: Companies that provide core AI capabilities across diagnostics, workflow automation, and population health – and that can integrate with major EHRs – are structurally positioned to benefit as AI becomes standard infrastructure rather than optional add-on.[1][2]
Selectively favor hospital operators with demonstrated digital execution: Systems that can show quantifiable gains from virtual care and AI (reduced length of stay, lower contract labor, improved revenue cycle) may command premium valuations over peers.
Focus on payers with disciplined AI utilization strategies: Insurers that leverage AI to improve care management and customer experience, while maintaining strong compliance in utilization management, will be better placed to manage medical cost trend and regulatory scrutiny.
Monitor evolving AI policy indices as a leading indicator: Tools like the Mount Sinai AI policy index can serve as an early signal for regulatory tightening or liberalization affecting specific AI use cases, from imaging diagnostics to automated decision support.[3]
Over the coming years, the outperformance within healthcare is likely to come less from exposure to “AI” as a label and more from the degree to which organizations can operationalize AI – embedding it in core workflows, reimbursement models, and risk management frameworks. As AI-driven virtual care and clinical decision support continue to scale across US health systems, investors will increasingly differentiate based on real-world evidence of productivity gains, patient outcomes, and regulatory resilience, rather than abstract innovation narratives.
